I-AASraw ivelisa i-NMN kunye ne-NRC powders ngobuninzi!

I-Ceritinib (LDK378)

Akukho kalo Udidi:

I-Ceritinib Powder isetyenziselwa ukunyanga abaguli abanesifo somhlaza wesifo semiphunga esincinci esincinci (i-NSCLC) abanesifo se-anaplastic lymphoma kinase (ALK) kwaye abanezilonda eziqhubela phambili okanye abangakwaziyo ukunyamezela iCrotinib (crizotinib).

Ingcaciso yeMveliso

Iimpawu ezisisiseko

Igama lemveliso I-Ceritinib (LDK378) ipowder
Inani leCAS 1032900-25-6
I-Molecular Formula Ikhowudi yemali
Ubukhulu beFormula 558.135
Iintetho ezifanayo LDK-378;

I-NVP-LDK378;

I-NVP-LDK378-NX;

5-Chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propan-2-ylsulfonyl)phenyl]pyrimidine-2,4-diamine.

Kubonakala Umhlophe ukuya kutsho-omhlophe
Ukugcina nokuPhatha Yigcine kubushushu begumbi kwaye kude nobushushu obuninzi kunye nokufuma.

 

ICeritinib (LDK378) Powderinkcazelo

I-Ceritinib powder isetyenziselwa unyango lwezigulana ezine-anaplastic lymphoma tumor-positive (ALK +) metastatic non-small cell cancer cancer (NSCLC) eye yanzima okanye ayinyamezelani ne-crizotinib emva konyango nge-crizotinib.

Ukulungelelaniswa kwakhona kwe-chromosomal kubandakanya i-anaplastic lymphoma kinase (ALK) njengomqhubi we-oncogenic kulutshintshe ngokupheleleyo unyango lomhlaza ongalunganga wesifo somhlaza. Kule minyaka ilishumi idlulileyo, iziyobisi ekujoliswe kuzo ziye zavela njengesicwangciso esisebenzayo esenzelwe ubuqu somhlaza womhlaza wemiphunga ongasasebenziyo. Ukuvunywa okukhawulezileyo kwee-ALK inhibitors ezinamandla, ezinje nge-crizotinib kunye ne-ceritinib (LDK378) yomgubo osele wenziwe kakuhle, ngokusekwe kwisilingo se-I / II esilungiswe kakuhle ibe yimpumelelo ebonakalayo kuphando lomhlaza weklinikhi kwaye inegalelo kwixesha elitsha lonyango olujolise kwi-oncogenic olubonakaliswe Uyilo oluhle lweklinikhi. I-ceritinib powder ukuba ibe yinto enamandla kwi-crizotinib ye-ALK-ehlelwe kwakhona yomhlaza wesifo somhlaza wamaphaphu.

 

I-Ceritinib (LDK378) ipowder Indlela yokuSebenza

I-Ceritinib powder isetyenziselwa ukunyanga abaguli abanesifo somhlaza wesifo se-metastatic non-small cell lung (NSCLC) abanesifo se-anaplastic lymphoma kinase (ALK) kwaye abanezilonda eziqhubela phambili okanye abangakwaziyo ukumelana neCrotinib (crizotinib).

I-Ceritinib powder yinto ekhethiweyo kunye ne-inhibitor enamandla ye-anaplastic lymphoma kinase (ALK). Kwi-physiology eqhelekileyo, imisebenzi ye-ALK njengenyathelo eliphambili kuphuhliso kunye nokusebenza kwethishu yenkqubo yemithambo-luvo. Nangona kunjalo, ukuhanjiswa kwe-chromosomal kunye nefusion kubangela ukuba ifom ye-ALK enoxgenic inyanzelisiwe kwinkqubela phambili ye-NSCLC. I-Ceritinib powder ke isebenza ukuthintela le enzyme iguqukileyo kwaye iyeke ukwanda kweseli, ekugqibeleni kumise ukuqhubela phambili komhlaza. Ngenxa yokuba i-ceritinib powder ithathwa njengonyango lomhlaza ekujoliswe kulo, uvavanyo oluvunyiweyo lwe-FDA luyafuneka ukumisela ukuba zeziphi izigulana ezingabagqatswa be-ceritinib powder. Olu vavanyo, oluveliswe nguRoche, yiVENTANA ALK (D5F3) CDx Assay kwaye isetyenziselwa ukuchonga abaguli be-ALK-positive NSCLC abaza kuxhamla kunyango lwe-ceritinib powder.

 

ICeritinib (LDK378) Powder isicelo

I-Ceritinib powder yi-anaplastic lymphoma kinase (ALK) -i-inhibitor efanelekileyo esetyenziselwa unyango lwe-NSCLC ye-metastatic. Ukusebenza njengokhetho oluphambili kwi-NSCLC yemastastatic.

 

ICeritinib (LDK378) Powder Iziphumo ebezingalindelekanga kunye nesilumkiso

Iziphumo ezibi ezimbi zibandakanya ityhefu yamathumbu, i-hepatotoxicity, isifo semiphunga esiphakathi, isifo se-QT sexesha elide, i-hyperglycemia, i-bradycardia kunye ne-pancreatitis.

Iziphumo ebezona zixeliweyo zixhaphakileyo sisifo sorhudo, isicaphucaphu, ii-enzyme zesibindi eziphakamileyo, ukugabha, iintlungu zesisu, ukudinwa, ukuncipha kokutya, kunye nokuqunjelwa. Ngenxa yomngcipheko wee-enzyme zesibindi eziphakanyisiweyo, iimvavanyo zomsebenzi wesibindi kufuneka zenziwe rhoqo kwiiveki ezimbini kwiiveki zokuqala ezili-9 zonyango.

Okokugqibela, i-ceritinib powder yomibini i-substrate kunye ne-inhibitor enamandla ye-enzyme CYP3A4, ke amayeza kufuneka abekwe esweni ngononophelo anokusebenzisana ne-ceritinib powder.

 

Biza ugqirha wakho kwangoko ukuba unayo:

▪ urhudo oluqatha;

▪ intloko ebuhlungu, ukudideka, ukutshintsha kwemo yengqondo, ukungaboni kakuhle, ukuxhuzula (ukuxhuzula);

▪ ukuchama kancinci okanye ukungabikho kwaphela;

Ukopha ngokungaqhelekanga (ukuphuma kwegazi, ukopha okunzima ukuya exesheni), okanye nakuphi na ukopha okungayi kuyeka;

Imiqondiso yokopha esiswini-igazi okanye isitulo sokulinda, ukukhohlela igazi okanye ukugabha okungathi yindawo yekofu;

▪ iingxaki zentliziyo-iintlungu esifubeni, iintlungu emhlathini okanye egxalabeni, ukudumba, ukukhawuleza ukutyeba, ukuziva uphefumla kancinci;

▪ Iimpawu zegazi elibalekileyo-ngesiquphe okanye ukuba buthathaka, iingxaki ngombono okanye intetho;

▪ iingxaki zesibindi-umchamo omnyama, ilindle elinombala wodongwe, ijundisi (ukuba mthubi kwesikhumba okanye amehlo);

▪ iqondo eliphantsi lekhalsiyam- ukuphazamiseka kwemisipha okanye ukucaphuka, ukuba ndindisholo okanye ukuziva ubambe (emlonyeni, okanye eminweni nasezinzwaneni);

▪ ukunyusa uxinzelelo lwegazi-intloko ebuhlungu, ukungaboni kakuhle, ukubetha entanyeni okanye ezindlebeni, unxunguphalo, ukopha ngeempumlo.

Unyango lwakho lomhlaza lunokulibaziseka okanye luyeke ngokupheleleyo ukuba uneziphumo ebezingalindelekanga.

 

isingqiniso

[1] “IZykadia (ceritinib powder) njengeeCapsule, zokuSebenzisa ngomlomo. Ulwazi oluGcweleyo lokuMisela ”(PDF). INovartis yoShishino lwaMayeza. Ukufunyanwa kwe-14 kaFebruwari 2017.

[2] “Amagama aMazwe ngaMazwe aNgenanto yakwenza nokuSebenzisa iziyobisi (INN). Kunconywe aMagama angaPhandle kokushishina: Uluhlu lwama-71 ”(PDF). I-World Health Organization. 2014. iphe. 79. Kubuyiswa umhla we-14 kuFebruwari 2017

[3] "I-FDA ivuma i-Ceritinib powder ye-ALK-Positive Lung Cancer". Ukuthintela. Epreli 29, 2014.

[4] "Ukuyalela idatha" (PDF). www.pharma.us.novartis.com. Ifunyenwe ngo-2019-06-12.

[5] "I-FDA yandisa iCeritinib powder Ukuvunywa komhlaza wemiphunga". IZiko leSizwe loMhlaza. 27 kweyeSilimela 2017.